325 related articles for article (PubMed ID: 17932553)
1. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.
Koyama H; Yamamoto H; Nishizawa Y
Mol Med; 2007; 13(11-12):625-35. PubMed ID: 17932553
[TBL] [Abstract][Full Text] [Related]
2. Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases.
Koyama H; Yamamoto H; Nishizawa Y
Biomark Insights; 2007 Sep; 2():331-9. PubMed ID: 19662215
[TBL] [Abstract][Full Text] [Related]
3. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
Nishizawa Y; Koyama H
J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
5. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging.
Yan SF; Ramasamy R; Schmidt AM
Biochem Pharmacol; 2010 May; 79(10):1379-86. PubMed ID: 20096667
[TBL] [Abstract][Full Text] [Related]
6. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Yamasaki Y
Diab Vasc Dis Res; 2008 Sep; 5(3):190-7. PubMed ID: 18777492
[TBL] [Abstract][Full Text] [Related]
7. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
8. Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
Santilli F; Vazzana N; Bucciarelli LG; Davì G
Curr Med Chem; 2009; 16(8):940-52. PubMed ID: 19275604
[TBL] [Abstract][Full Text] [Related]
9. Soluble forms of RAGE in internal medicine.
Vazzana N; Santilli F; Cuccurullo C; Davì G
Intern Emerg Med; 2009 Oct; 4(5):389-401. PubMed ID: 19727582
[TBL] [Abstract][Full Text] [Related]
10. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products.
Quade-Lyssy P; Kanarek AM; Baiersdörfer M; Postina R; Kojro E
J Lipid Res; 2013 Nov; 54(11):3052-61. PubMed ID: 23966666
[TBL] [Abstract][Full Text] [Related]
11. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
12. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.
Romero R; Espinoza J; Hassan S; Gotsch F; Kusanovic JP; Avila C; Erez O; Edwin S; Schmidt AM
J Perinat Med; 2008; 36(5):388-98. PubMed ID: 18593373
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
14. [Possible participation of advanced glycation endproducts and their receptor system in the development of diabetic vascular complications].
Yamamoto Y; Sakurai S; Watanabe T; Yonekura H; Yamamoto H
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):49-55. PubMed ID: 12617038
[TBL] [Abstract][Full Text] [Related]
15. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation.
Lanati N; Emanuele E; Brondino N; Geroldi D
Curr Vasc Pharmacol; 2010 Jan; 8(1):86-92. PubMed ID: 19485931
[TBL] [Abstract][Full Text] [Related]
16. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
[TBL] [Abstract][Full Text] [Related]
17. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
18. Activation of the receptor for advanced glycation end products system in women with severe preeclampsia.
Oliver EA; Buhimschi CS; Dulay AT; Baumbusch MA; Abdel-Razeq SS; Lee SY; Zhao G; Jing S; Pettker CM; Buhimschi IA
J Clin Endocrinol Metab; 2011 Mar; 96(3):689-98. PubMed ID: 21325454
[TBL] [Abstract][Full Text] [Related]
19. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.
Prasad K
Int J Angiol; 2014 Mar; 23(1):11-6. PubMed ID: 24627612
[TBL] [Abstract][Full Text] [Related]
20. Receptor for advanced glycation end products (RAGE) in vascular and inflammatory diseases.
Mahajan N; Dhawan V
Int J Cardiol; 2013 Oct; 168(3):1788-94. PubMed ID: 23722052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
